Centrus Energy (LEU): Upgrade to Buy After a Clear Reset — Tactical Entry and Plan

Hook and thesis

Centrus Energy (LEU) has been punished hard in recent weeks, slicing through moving averages and dragging price from last year's $464 peak to the current $147 area. That selloff -- painful for early owners -- has also pulled the risk-reward into a range where an upgrade to a tactical buy makes sense. The company's scale in low-enriched uranium (LEU) supply, a $4.5 billion backlog that extends to 2040, and explicit federal support for domestic enrichment create a structural demand tailwind that the market is now under-pricing.

I'm upgrading LEU to a Buy for a position trade with clearly defined entry, target and stop-loss levels. This is not a fundamental endorsement without caveats: earnings and cash flow are volatile, margins deteriorated last quarter and the company carries leverage. Still, the current market cap of roughly $3.01 billion and enterprise value near $2.40 billion imply investors are pricing a lot of downside; I see a path to meaningful upside if Centrus executes on backlog conversion and controls near-term spending.

What Centrus does and why it matters

Centrus supplies nuclear fuel and services through two main segments: LEU sales to utilities and Technical Solutions that includes engineering and fuel production capabilities for existing and next-gen reactors. The market cares because the U.S. and global nuclear programs are shifting from idle capacity to expansion: policy support, interest in small modular reactors (SMRs), and rising power demand from data centers and electrification are all increasing demand for domestically sourced enriched uranium and HALEU-capable fuel services.

Fundamentals and recent trends

The company reported Q2 results showing revenue of $176.1 million, up 14% year-over-year, and reaffirmed full-year 2026 revenue guidance of $450-$500 million. Those are positive top-line signals. The near-term sour note is margin pressure: cost of sales rose 25% and SG&A surged 96% as Centrus invests to expand capacity and commercialize new agreements such as the X-energy arrangement. Operating income dropped 69% year-over-year, and free cash flow is negative at roughly -$163.8 million—clear evidence that growth is being funded by cash burn and likely balance-sheet activity.

Balance-sheet and valuation pointers: market capitalization is about $3.01 billion with enterprise value near $2.40 billion. Reported trailing earnings per share was about $2.37, and the company currently trades at a high single-digit to low-double-digit multiple on various measures: snapshot P/E sits around 69x while other estimates show mid-60s depending on timing. Debt-to-equity runs about 1.39, reflecting leverage that matters in a cash-burning expansion phase. Short interest has been elevated recently with roughly 5.42 million shares short as of 09/15/2026 and days-to-cover near 7 on recent volumes, which means short squeezes are possible on positive catalysts but also increases downside pressure if growth disappoints.

Valuation framing

At a current price of $147.32 the market is implicitly assigning a high execution premium to Centrus given its backlog and growth trajectory. That premium looks vulnerable: operating income contraction and negative free cash flow validate some of the caution. But the $4.5 billion backlog provides revenue visibility over many years; if Centrus can convert backlog at reasonable margins, the current EV-to-sales multiple (~5.07x) and EV/EBITDA (stretched given recent hits) will look generous rather than punitive. In plain terms: the company currently trades like a high-growth industrial with execution risk priced in. The recent selloff reduced headline multiples and created a tactical entry before the market fully prices in contract wins or smoother margins.

Trade plan (actionable)

Direction: Long LEU.

This trade is structured as a position intended to play out over up to 180 trading days. I outline specific time slices to guide management of the position:

• Short term (10 trading days) - Expect continued volatility. Use this window to scale in if there is further weakness toward the stop price or to reduce size on any sharp gap up on headline-driven squeezes.
• Mid term (45 trading days) - Look for early signs of margin stabilization (gross margin expansion, moderation in SG&A) and progress on key contracts such as X-energy. A move above the 50-day average (~$168.52) would be constructive and warrant adding to the position if accompanied by improving volume.
• Long term (180 trading days) - The full thesis depends on backlog conversion and cash-flow repair. If Centrus sustains revenue toward the $450-$500 million guidance and demonstrates falling per-unit costs, the case for re-rating toward more normal industrial multiples supports the $210 target.

Catalysts

• Backlog conversion milestones and new contract announcements that increase visibility on 2027-2030 revenue streams.
• Operational updates showing improved production costs or better-than-expected enrichment yields that expand gross margins.
• Evidence of reduced SG&A as a percentage of revenue after initial expansion spending; management signaling disciplined capital allocation.
• Positive policy or federal funding developments accelerating domestic HALEU supply projects or reactor buildouts.

Risks and counterarguments

Be blunt: this trade is not risk-free. Investors are being paid for taking on execution and macro risk.

• Execution risk: Management is expanding capacity and integrating new commercial agreements. If expansion falters, cost overruns or slower-than-expected production can further pressure margins and cash flow. Recent results already showed a 25% increase in cost of sales and a 96% jump in SG&A.
• Cash-flow and leverage: Free cash flow was negative at about -$163.8 million and debt-to-equity is elevated at ~1.39. Continued cash burn would force dilution, asset sales, or expensive refinancing if revenue and margins do not improve.
• Valuation sensitivity: The stock trades at a high trailing P/E that assumes future earnings growth and margin recovery. If earnings disappoint, multiples can compress further from current levels and wipe out the expected upside.
• Market and sentiment risk: Short interest is material (roughly 5.4 million shares with days-to-cover near 7 on recent volume). That can amplify downside on negative headlines and accelerate selling momentum; it can equally amplify upside on positive surprises, but the risk of abrupt moves is real.
• Sector/commodity risk: Broader uranium and nuclear supply dynamics, including production disruptions at peers or changes in reactor build expectations, can materially affect Centrus's contract pricing and timing.

Counterargument: Skeptics will point out that the company is re-investing aggressively without demonstrable, immediate margin gains and that the free cash flow profile makes the equity sensitive to any revenue slip. If you believe execution will remain uneven and federal support could be slower or contested, the current multiple is not justified. That is a legitimate position and is why a strict stop-loss at $134 is part of the plan.

What would change my mind

I would re-evaluate or downgrade this trade if any of the following occur:

• Management withdraws or materially lowers 2026 revenue guidance below the $450-$500 million band.
• Free cash flow does not show meaningful improvement over the next two quarters and leverage increases materially (debt-to-equity rising well above 1.5 without a credible deleveraging plan).
• Backlog cancellations or significant slippage in contract delivery dates that reduce the multi-year visibility the company currently cites.

Conclusion

LEU is a company with a structural role in a secularly supportive industry. The recent selloff materially reduces the market's expectations and, with a disciplined entry and stop, creates a tradeable long with attractive asymmetry. The risks are real and meaningful: weak margins, negative free cash flow and leverage mean this is not a buy-and-forget idea. For investors comfortable with execution risk, a position-sized allocation at $147.32 with a $134 stop and a $210 target over a 180-trading-day horizon offers a sensible play on backlog conversion and nascent recovery in margins.

Trade size this idea so that a stop-triggered loss is a manageable portion of your portfolio — the scenario where this thesis fails is not a technical dip but a fundamental deterioration in revenue conversion and cash flow, and the stop is calibrated to protect against that outcome.

Key metrics at a glance

Final thought

I expect a period of continued headline-driven volatility. That noise can be used to build a position below the entry price or to trim into strength. The central trade thesis is simple: the market has priced meaningful execution risk into LEU; if Centrus stabilizes margins, converts backlog at reasonable rates and re-aligns cash flow, the stock can rerate toward a valuation that reflects a unique domestic supplier in a constrained market. For disciplined traders willing to accept the liquidity and execution risks, the current level is an attractive tactical entry.